Audited Consolidated Financial Results for the Half year and year ended 31.03.2026

Date: 24th July, 2026 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 544409 ISIN: INE0TG901011 SUBJECT: OUTCOME OF THE MEETING OF THE BOARD OF DIRECTORS OF ASTONEA LABS LIMITED HELD ON 24th JULY, 2026 Pursuant to the provisions of Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors of Astonea Labs Limited ("the Company"), at its meeting held on Friday, 24th July, 2026, at the Corporate Office of the Company situated at 63, Industrial Area, Phase-II, Panchkula, Haryana - 134113, inter alia, considered, deliberated upon and approved the following matters: 1. APPROVAL OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR AND FINANCIAL YEAR ENDED 31ST MARCH, 2026 The Board of Directors, at its meeting held on 24 July, 2026, considered and approved the Audited Consolidated Financial Results of the Company for the half year and financial year ended 31st March, 2026, together with the Audited Consolidated Financial Statements comprising the Consolidated Balance Sheet, Consolidated Statement of Profit and Loss, Consolidated Statement of Cash Flows and the Notes forming part thereof, and took on record the Statutory Auditors' Report issued thereon containing an unmodified opinion. The Board further approved the declaration pursuant to Regulation 33(3)(d) of the SEBI Listing Regulations, confirming that the Statutory Auditors have expressed an unmodified opinion on the aforesaid Audited Consolidated Financial Results and authorised the submission thereof to the Stock Exchange. The Board further noted that the Audited Consolidated Financial Results for the financial year ended 31st March, 2026 could not be considered and approved at its earlier meeting held on 30th May, 2026 since the audit report of the Associate Company was still awaited at the time of the Board Meeting. Accordingly, only the Audited Standalone Financial Results of the Company for the financial year ended 31st March, 2026 were considered and approved at the said meeting. Upon receipt of the audited financial statements of the Associate Company i.e. Damaira Pharmaceuticals Private Limited, the Board has now duly considered and approved the Audited Consolidated Financial Results at the present meeting. The Board further noted that, pursuant to the resolution passed at its meeting held on 25th May, 2026, Mr. Pardeep Dalal (DIN: 02424111) was duly authorised as the signing authority on behalf of the Company for signing and certifying the Financial Results in accordance with the requirements of Regulation 33 of the SEBI Listing Regulations. The Company had already intimated the aforesaid authorisation to the Stock Exchange vide its response dated 20th June, 2026, submitted against the GSTIN NO.: 06AAPCA4446E1ZP I CIN: L24304CH2017PLC041482 (Formely known as Astonea Labs Private Limited) Reg.Off: SCO 321-322, Basement, Sector 35B, Chandigarh, India-160022 Corporate Office: 63, Industrial Area, Phase II, Panchkula, Haryana, India-134113 Plant: Village Haripur, Teh. Raipur Rani, Distt., Panchkula, India-134204 Mobile No.:+91 7888 491 385, Email: info@astonea.org, Website: www.astonea.org query/email received from the Stock Exchange dated 19th June, 2026. Accordingly, the Audited Consolidated Financial Results approved at the present meeting have been signed and certified by the said authorised signatory in accordance with the aforesaid Board authorisation. The Board further noted that the Trading Window for dealing in the securities of the Company, which has remained closed with effect from 01st April, 2026 pursuant to the provisions of the Company's Code of Conduct for Prevention of Insider Trading and the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, shall stand reopened upon expiry of 48 (Forty-Eight) hours from the declaration and approval of the Audited Consolidated Financial Results of the Company for the half year and financial year ended 31st March, 2026. For more details, kindly refer Annexure-I containing Audited Consolidated Financial Results. 2. APPROVAL OF BOARD’S REPORT FOR THE FINANCIAL YEAR 2025-26 The Board of Directors considered, reviewed and approved the draft Board’s Report of the Company for the financial year ended 31st March, 2026, along with the annexures forming part thereof, as placed before the Board. After due deliberation and review, the Board approved and adopted the said Board’s Report in accordance with the provisions of Section 134 and other applicable provisions of the Companies Act, 2013 read with the rules made thereunder. The Board’s Report, as approved, contains the requisite disclosures, statements and information as required under the applicable provisions of the Companies Act, 2013, rules framed thereunder and other applicable statutory requirements. 3. APPROVAL OF ANNUAL REPORT FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2026 The Board of Directors considered, reviewed and approved the Annual Report of the Company for the financial year ended 31st March, 2026 (“Financial Year 2025-26) as placed before the Board. The said Annual Report comprises, inter alia, the Audited Financial Statements of the Company, Board’s Report, Statutory Auditors’ Report and other statements, disclosures, certificates and information forming an integral part thereof, as required under the applicable provisions of the Companies Act, 2013, the rules made thereunder and other applicable statutory and regulatory requirements. After due deliberation and review, the Board approved and adopted the Annual Report of the Company for the financial year ended 31st March, 2026, and authorised the Directors of the Company to sign and authenticate the same on behalf of the Board of Directors in accordance with the applicable provisions of the Companies Act, 2013. 4. RETIREMENT BY ROTATION AND RECOMMENDATION FOR RE-APPOINTMENT OF MS. POOJA SINGH (DIN: 10547745) AS DIRECTOR OF THE COMPANY The Board of Directors, pursuant to the provisions of Section 152 and other applicable provisions of the Companies Act, 2013 read with the rules made thereunder, took note of the retirement by rotation of Ms. Pooja Singh (DIN: 10547745), Director of the Company, at the ensuing Annual General Meeting of the Company. The Board further noted that Ms. Pooja Singh, being eligible for re-appointment and having offered herself for re-appointment as a Director of the Company, has submitted her consent and requisite declarations in accordance with the applicable provisions of the Companies Act, 2013 and rules made thereunder. GSTIN NO.: 06AAPCA4446E1ZP I CIN: L24304CH2017PLC041482 (Formely known as Astonea Labs Private Limited) Reg.Off: SCO 321-322, Basement, Sector 35B, Chandigarh, India-160022 Corporate Office: 63, Industrial Area, Phase II, Panchkula, Haryana, India-134113 Plant: Village Haripur, Teh. Raipur Rani, Distt., Panchkula, India-134204 Mobile No.:+91 7888 491 385, Email: info@astonea.org, Website: www.astonea.org After due consideration and deliberation, the Board considered and recommended the proposal for re- appointment of Ms. Pooja Singh as a Director of the Company for consideration and approval of the members at the ensuing Annual General Meeting of the Company in accordance with the applicable provisions of the Companies Act, 2013. For more details, kindly refer Annexure-II. 5. ALTERATION OF OBJECT CLAUSE OF THE MEMORANDUM OF ASSOCIATION (MOA) OF THE COMPANY The Board of Directors considered and approved the proposal for alteration of the Object Clause (Clause III(A)) of the Memorandum of Association (“MOA”) of the Company pursuant to the provisions of Section 13 and other applicable provisions, if any, of the Companies Act, 2013 read with the rules made thereunder. The Board approved [Showing first 8,000 characters — download PDF for full document]